Agios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019 Read more about Agios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019
Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy Read more about Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy
Agios to Present Clinical Data from its IDH Program at ASCO Read more about Agios to Present Clinical Data from its IDH Program at ASCO
Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients Read more about Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients
Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy Read more about Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy
Agios Reports Business Highlights and First Quarter 2019 Financial Results Read more about Agios Reports Business Highlights and First Quarter 2019 Financial Results
Agios to Webcast Conference Call of First Quarter 2019 Financial Results on May 2, 2019 Read more about Agios to Webcast Conference Call of First Quarter 2019 Financial Results on May 2, 2019
Agios Announces New Commercial Leadership Structure Read more about Agios Announces New Commercial Leadership Structure
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy Read more about Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy
Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call Read more about Q1 2019 Agios Pharmaceuticals Inc Earnings Conference Call